logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

Why the Current Interest in Ventyx Biosciences

The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus   We like the fact that Ventyx Biosciences ( VTYX ) is not just focusing on developing innovative oral Drugs for people living with autoimmune and inflammatory disorders, but also...

Read More

March 7, 2023

0

Encouraging News from Hoth Therapeutics and Kintor Pharmaceutical Ltd About Treating Acne and Alopecia

Hoth Therapeutics Hoth Therapeutics ( HOTH ) announced that its product, HT-003, has yielded positive results in an in vivo  acne therapeutic  model. The model showed that HT-003 reduces the expression of toll-like receptor 2 ( TLR2 ), which happens...

Read More

July 14, 2021

0

Our Eyes Are on Reata Pharmaceuticals Today

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals ( RETA ) announced a setback of its chronic kidney disease product known as bardoxolone. The failure of this drug occurred after Reata's product Skyclaris was FDA approved for the treatment of Friedrich's...

Read More

May 25, 2023

0

The U.S. FDA Accepts Exelixis sNDA of CABOMETYX® for Priority Review

Exelixis sNDA Accepted by the US FDA for CABOMETYX ® The U.S. Food and Drug Administration ( FDA ) accepted Exelixis ( EXEL ) supplemental New Drug Application ( sNDA ) for CABOMETYX ® (cabozantinib) as a treatment for patients...

Read More

August 6, 2021

0

Gain Therapeutics: A Biotech with Promising Treatments for Neurodegenerative Diseases and a Note from Prohost Biotech

Gain Therapeutics Inc in the News Gain Therapeutics, Inc. ( GANX ) announced today topline data from its  study conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators ( STARs...

Read More

September 8, 2021

0

Immunovent, Altimmune and Soleno: A Summary of Three Firms We Believe Have Promising Technologies and Treatments

Immunovent, Altimmune & Soleno In addition to Vertex ( VRTX ) , Crispr Therapeutics ( CRSP )  and Acturus Therapeutics ( ARCT ) , the following summaries are of three firms we believe have promising Products  1. Immunovent The phase...

Read More

December 27, 2023

0

Why Jounce Therapeutics Stock is Outperforming Today

Jounce Therapeutics Jounce Therapeutics ( JNCE ) is a clinical-stage immunotherapy company developing therapies enabling the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce has ongoing multiple development stage programs while simultaneously...

Read More

September 14, 2021

0

Vertex Pharmaceuticals Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals Updates Vertex Pharmaceuticals ( VRTX ) announced multiple program updates ahead of the upcoming investor meetings in January, including the 42 Annual J.P. Morgan Healthcare Conference, which took place on January 8, 2024. From Vertex Pharmaceuticals Reshma Kewalramani,...

Read More

January 9, 2024

0

OKYO Pharma Limited: Another Ophthalmology Firm with Promising Eye Treatment

Improving eyesight is speeding towards treating devastating eye diseases from the Retina in the back of the eye to the cornea on the front surface of the eye. As we wrote in Prohost Letter #457 , the current biotechnology revolution...

Read More

January 11, 2024

0

The Time Has Come to Present Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc ( MIRM ) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Maralixibat, is Mirum Pharmaceuticals lead product candidate. The product...

Read More

September 27, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 11
  • 12
  • 13
  • ...
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy